Condition: Breast Neoplasms · Breast Cancer · Sponsor: Merck Sharp & Dohme LLC
Researchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. The main goals of this study are to learn: * About the safety of the study treatments and if people tolerate them * If people who receive patritumab deruxtecan, pembrolizumab, and chemotherapy before surgery have fewer cancer cells removed during surgery compared to those who receive only pembrolizumab (pembro) and chemotherapy.
This description comes directly from the study's public registry record.
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
Always discuss trial participation with your own doctor first.
| UCLA Hematology/Oncology - Parkside ( Site 0021) | Santa Monica, California, United States | Recruiting |
| Orchard Healthcare Research Inc. ( Site 0006) | Skokie, Illinois, United States | Recruiting |
| Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0003) | Billings, Montana, United States | Recruiting |
| Northwest Cancer Specialists (Compass Oncology) ( Site 8003) | Tigard, Oregon, United States | Recruiting |
| SCRI Oncology Partners ( Site 7000) | Nashville, Tennessee, United States | Recruiting |
| Texas Oncology - DFW ( Site 8000) | Dallas, Texas, United States | Recruiting |
| Houston Methodist Hospital ( Site 0022) | Houston, Texas, United States | Recruiting |
| Virginia Oncology Associates (VOA) ( Site 8001) | Norfolk, Virginia, United States | Recruiting |
| Seoul National University Hospital ( Site 2400) | Seoul, South Korea | Recruiting |
| Severance Hospital, Yonsei University Health System ( Site 2402) | Seoul, South Korea | Recruiting |
| Asan Medical Center ( Site 2401) | Seoul, South Korea | Recruiting |
| Institut Català d'Oncologia (ICO) - Badalona ( Site 1700) | Badalona, Catalonia, Spain | Recruiting |
+ 5 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06797635